Browse Drug Recalls
629 FDA drug safety recalls.
FDA Drug Recall Enforcement Database
Browse 629 FDA drug recall enforcement actions. Each entry includes the product description, reason for recall, classification (Class I through III based on severity), recalling firm, and distribution details. Use the filters below to search by year, classification, state, or keyword.
Drug Safety Recalls
Browse 629 FDA drug recalls in OH.
| Date | Product | Reason | Class | Firm |
|---|---|---|---|---|
| Aug 24, 2026 | Ramipril Capsules USP, 10 mg, packaged in a) 100 Capsules (NDC 76282-673-01) ... | Failed Impurities/Degradation Specifications: OOS result obtained for a process impurity, dicyclo... | Class II | Hikma Pharmaceuticals USA INC. |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 100 Tablets (10 x 10 ... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 10 Tablets (10 x 1) uni... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 100 Tablets (10 x 10 ... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 112 mcg (0.0112 mg), 100 Tablets (10 x 10 ... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 10 Tablets (10 x 1) uni... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 50 mcg (0.050 mg), 100 Tablets (10 x 10 un... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 25 mcg (0.025 mg), 100 Tablets (10 x 10 un... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 125 mcg (0.0125 mg), 10 Tablets (10 x 1) u... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 100 Tablets (10 x 10 un... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 88 mcg (0.088 mg), 100 Tablets (10 x 10 un... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 150 mcg (0.0150 mg), 10 Tablets (10 x 1) u... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jul 13, 2026 | Levothyroxine Sodium Tablets, USP, 75 mcg (0.075 mg), 10 Tablets (10 x 1) uni... | Subpotent Drug | Class II | Major Pharmaceuticals |
| Jun 16, 2026 | Carton Label: MAJOR, Methylergonovine Maleate Tablets, USP, 0.2 mg, 20 TABLET... | Subpotent Drug | Class II | The Harvard Drug Group LLC |
| May 1, 2026 | Vitamin B-Complex, Vitamin C & Folic Acid Dietary Supplement Oral Liquid, Con... | Presence of a Foreign Substance; black particles observed in liquid | Class II | Safecor Health, LLC |
| May 1, 2026 | Primidone Tablets, USP, 250 mg, 100 Tablets (10 x 10 unit dose blister) per c... | Cross contamination with other products: API contaminated with trace amounts of Acemetacin API. | Class III | Amerisource Health Services LLC |
| May 1, 2026 | Primidone Tablets, USP, 50 mg, 100 Tablets (10 x 10 unit dose blister) per ca... | Cross contamination with other products: API contaminated with trace amounts of Acemetacin API. | Class III | Amerisource Health Services LLC |
| Apr 30, 2026 | Atomoxetine Capsules HCL, 10 mg Capsules in unit dose foil strip, strips are ... | Labeling: Label Mix-Up: Atomoxetine HCl 25mg Capsule incorrectly labeled as Atomoxetine HCl 10mg ... | Class II | Safecor Health, LLC |
| Apr 16, 2026 | Levocarnitine Injection, USP, 1 g/5 mL (200 mg/mL), 5 mL Single-Dose Vial, Fo... | Labeling: Missing Label | Class III | American Regent, Inc. |
| Apr 9, 2026 | Omega-3-Acid, Ethyl Esters, Capsules, USP, 1 gram, 50 capsules (5 x 10 unit d... | Failed Capsule Specifications: Out of specification results obtained during routine stability tes... | Class II | The Harvard Drug Group LLC |
| Apr 7, 2026 | Alendronate Sodium Oral Solution, 70 mg/75 mL, 75 mL, Rx only, 4 x 75 mL Sing... | This recall is being conducted due to out of specification assay results in a limited number of b... | Class II | Hikma Pharmaceuticals USA INC |
| Mar 24, 2026 | Memantine Hydrochloride Extended-Release, Capsules, 7 mg, 100 Capsules (10 x ... | Failed Dissolution Specifications | Class II | The Harvard Drug Group LLC |
| Mar 16, 2026 | Meclizine Hydrochloride Tablets, USP 12.5 mg, (a) 50 Tablets [5 x 10] (NDC 60... | Failed tablet specifications. | Class II | Amerisource Health Services LLC |
| Feb 17, 2026 | Midodrine Hydrochloride Tablets, USP, 5 mg, 50 Tablets (5 x 10 blister packs)... | Defective container; inadequately sealed blister packaging. | Class II | The Harvard Drug Group LLC |
| Feb 12, 2026 | Eptifibatide Injection, 75 mg/100 mL vial for weight-adjusted bolus dosing, 1... | Labeling: Not Elsewhere Classified. The carton for Eptifibatide Injection 75 mg/100 mL states 75 ... | Class III | Slate Run Pharmaceuticals |
| Jan 14, 2026 | Oxycodone Hydrochloride Tablets, USP (CII), 5 mg, 100-Count (10 x 10) bliste... | Defective container: Multiple customer complaints received for card seal defects observed on the ... | Class II | Amerisource Health Services LLC |
| Oct 16, 2025 | Prazosin Hydrochloride, Capsules, USP, 1 mg, 100 capsules (10x10) cartons, Rx... | Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the ... | Class II | Amerisource Health Services LLC |
| Oct 16, 2025 | Prazosin Hydrochloride, Capsules, USP, 2 mg, 100 capsules (10x10) cartons, Rx... | Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the ... | Class II | Amerisource Health Services LLC |
| Oct 16, 2025 | Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx on... | Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the ... | Class II | Amerisource Health Services LLC |
| Oct 10, 2025 | Gabapentin Capsules, USP, 100 mg, 100 Capsules (10 x 10 blister packs), Rx on... | Failed Impurities/Degradation Specifications: an out of specification result obtained during rout... | Class II | The Harvard Drug Group LLC |
| Oct 10, 2025 | Gabapentin Capsules, USP, 100 mg, 10 Capsules (10 x 1 blister pack), Rx only,... | Failed Impurities/Degradation Specifications: an out of specification result obtained during rout... | Class II | The Harvard Drug Group LLC |
| Oct 9, 2025 | Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by... | CGMP Deviations: The recalling firm filed for Chapter 11 on September 30, 2024. As a result, it c... | Class II | Amerisource Health Services LLC |
| Sep 22, 2025 | Bevacizumab 1.75 mg/0.07 mL - 0.25 mL syringe, Intravitreal, 0.07 mL Total Vo... | Lack of assurance of sterility. | Class II | RC Outsourcing, LLC |
| Sep 15, 2025 | Carbamazepine Extended-Release Tablets, USP 400 mg, 30 Tablets per carton (3x... | Failed Dissolution Specifications. | Class II | Amerisource Health Services LLC |
| Aug 27, 2025 | chlorproMAZINE Hydrochloride Tablets, USP, 25 mg, packaged as a) 50 (5x10) bl... | Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packa... | Class II | Amerisource Health Services LLC |
| Aug 27, 2025 | chlorproMAZINE Hydrochloride Tablets, USP, 100 mg, 100 (10x10) blisterpack pe... | Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packa... | Class II | Amerisource Health Services LLC |
| Aug 27, 2025 | chlorproMAZINE Hydrochloride Tablets, USP, 50 mg, 100 (10x10) blisterpacks, R... | Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packa... | Class II | Amerisource Health Services LLC |
| Aug 27, 2025 | chlorproMAZINE Hydrochloride Tablets, USP, 200 mg, 100 (10x10) blisterpack pe... | Presence of a foreign substance.A specific lot of auxiliary polyester coil, used in product packa... | Class II | Amerisource Health Services LLC |
| Aug 5, 2025 | Enoxaparin Sodium Injection, USP, 30 mg/0.3 mL, packaged in 0.3 mL prefilled ... | Correct Labeled Product Mispack: Bags labeled for Enoxaparin Sodium Injection, 80 mg/0.8 mL, cont... | Class II | Cardinal Health Inc. |
| Jul 30, 2025 | Xolair (omalizumab injection), 150 mg/ml, 1 auto-injector, Rx only, Genentech... | CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requi... | Class II | Cardinal Health Inc. |
| Jul 30, 2025 | Xolair (omalizumab injection), 75 mg/0.5 ml, Rx only, Genentech, Inc., South ... | CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requi... | Class II | Cardinal Health Inc. |
| Jul 30, 2025 | RECOMBINATE, [Antihemophilic Factor (Recombinant)], 5 mL vials, Rx Only, Take... | CGMP Deviations - Product was exposed to temperatures outside the product's labeled storage requi... | Class II | Cardinal Health Inc. |
| Jul 29, 2025 | Sucralfate Tablets, USP 1 gram, 100 Tablets, (10x10), Rx Only, Distributed by... | CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it canno... | Class II | Amerisource Health Services LLC |
| Jul 11, 2025 | Sucralfate Tablets, USP 1 gram, packaged in a) 100-count bottles NDC 29033-00... | CGMP Deviations: The recalling firm filed for Chapter 11 in September 2024. As a result, it canno... | Class II | Nostrum Laboratories, Inc. |
| Jun 19, 2025 | Gabapentin Capsules, USP, 100 mg, 10 capsules (10x1) per bag, Rx only, Packag... | Defective container; blister packaging inadequately sealed. | Class II | The Harvard Drug Group LLC |
| Jun 19, 2025 | Gabapentin Capsules, USP, 100 mg, 100 capsules (10x10), blister pack cartons,... | Defective container; blister packaging inadequately sealed. | Class II | The Harvard Drug Group LLC |
| May 15, 2025 | Indomethacin Extended-Release Capsules, USP, 75 mg, 30 capsules (3 x 10 blist... | cGMP deviations | Class II | Amerisource Health Services LLC |
| Apr 18, 2025 | niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Sing... | Lack of sterility assurance: Product leakage around the vial neck, which could potentially result... | Class II | American Regent, Inc. |
| Apr 18, 2025 | niCARdipine Hydrochloride Injection, USP, 25 mg/10 mL (2.5 mg/mL), 10 mL Sing... | Lack of sterility assurance: Product leakage around the vial neck, which could potentially result... | Class II | American Regent, Inc. |
| Apr 9, 2025 | Wegovy (semaglutide) injection, 2.4 mg/0.75 mL, 4 Single-Dose Prefilled Pens ... | Temperature abuse: Wegovy product was potentially exposed to temperatures outside of the products... | Class II | Cardinal Health Inc. |
Frequently Asked Questions
When a drug safety issue is identified, through FDA inspections, laboratory testing, adverse event reports, or manufacturer quality checks, the responsible company issues a recall to remove the affected products from the market. Pharmacies pull the product from shelves, and consumers are advised to contact their healthcare provider for alternatives.
The leading causes include cGMP deviations, impurity contamination (including nitrosamines like NDMA), failed dissolution or stability testing, sterility issues, potency problems, labeling errors, and foreign particle contamination.
Use the search and filter tools on this page to look up specific medications, active ingredients, or manufacturers. Each recall entry includes the product description, lot numbers, and distribution details.